Cujo Posted - 04/06/24

$IDXG this is a good example of how market makers manipulate price before news. The red lines are bollinger bands, and the grey is Keltner channels at 1.5 std dev. MM first brought up the lower BB, then on Friday shot the price up high and then pulled it back down to bring the upper BB in below the Keltner channel to put the stock in a squeeze

pilobious Posted - 04/05/24

$IDXG “Long suffering shareholders teased with 10 minute rally in share price” headline.

apppro Posted - 04/05/24

$IDXG oh well

Zapp Posted - 04/05/24

$IDXG finally

Cujo Posted - 04/05/24

$IDXG bollinger bands are getting pulled in, my guess is that we get news next week

davoid49 Posted - 04/05/24

$IDXG So likely an orchestrated pump. never fails

davoid49 Posted - 04/05/24

$IDXG $2.60 and still climbing bid/ask is insane and looks stalled

apppro Posted - 04/05/24

$IDXG LOL - last to know is stocktwits - look at their price

davidb1010 Posted - 04/05/24

$IDXG LETS GO !!!! 🦾

apppro Posted - 04/05/24

$IDXG

pilobious Posted - 04/05/24

$IDXG no SEC filing today. Retail last to know whatever it is.

apppro Posted - 04/05/24

$IDXG $2.22 trading now

davoid49 Posted - 04/05/24

$IDXG Not seeing any news to justify this move... Keep it going.

Waters59 Posted - 4 weeks ago

$IDXG This is embarrassing. 4 quarters now of great earnings and this share price cant breakout. Need a new PR person or Team.

Waters59 Posted - 03/22/24

$IDXG my god, what's it gonna take for this to keep going up? This is 4 qts now they crushed it.

Waters59 Posted - 03/13/24

$IDXG Let's get this share price above ATH!!

Esau815 Posted - 03/10/24

$IDXG Question. If Novitas agrees to continue PancraGen reimbursement, how high does the common share price jump to? It's a huge, huge issue and it's the only issue holding back the stock price.

pilobious Posted - 03/08/24

$IDXG I’m back in for the first time since that $6.60 special rights offering was pulled. Turns out they didn’t need it. The equity holders were going stand in for those who declined to participate. They should just take the company private instead.

davidb1010 Posted - 03/07/24

$IDXG Finally some movement. Great results after that depressing pull down. Still holding still 2013. #bullish

Esau815 Posted - 03/07/24

$IDXG Zapp....You're making a critical error by ignoring the 7.6MM preferred shares with a preference of $6. And don't forget about the $7MM in debt. It was a very good quarter. We're still hostage to the CMS issue. Presently, the enterprise value with a $6 pref and the $7MM debt is roughly $54MM.

Zapp Posted - 03/07/24

$IDXG market cap of 4.5M is ridiculously low. With low float this should be a 10 bagger +

apppro Posted - 03/07/24

$IDXG

DonCorleone77 Posted - 03/07/24

$IDXG Interpace Biosciences reports Q4 EPS 19c vs. (33c) last year Reports Q4 revenue $10.3M vs. $8.3M last year. "2023 marked the 3rd consecutive year of price-adjusted revenue and profitability growth for the Company" said Tom Burnell, President and CEO. "Revenue and adjusted EBITDA for 2023 were $40.2 million and $5.4 million improving 26% and 463% versus the prior year, respectively." Burnell further said, "Continued reliance by physicians and patients on the use of molecular diagnostics for risk stratification of pancreatic and thyroid cancer is evident with continued adoption of the Company's PancraGEN and ThyGeNEXT + ThyraMIR v2 tests." Mr. Burnell added: "These results are even more impressive given the challenges imposed upon numerous diagnostics companies in 2023 related to proposed changes to Medicare reimbursement for many diagnostic tests, including Interpace's PancraGEN/PathFinderTG assay for pancreatic cancer...."

apppro Posted - 03/07/24

$IDXG

apppro Posted - 03/07/24

$IDXG Interpace if this was nvda it would be UP 500% in pre market https://ir.interpace.com/press-releases/detail/231/interpace-biosciences-announces-preliminary-full-year-and

Esau815 Posted - 2 months ago

$IDXG The company's future rests on the PancraGen reimbursement decision. I think they have a legitimate shot of saving it given the Kyoto guidelines supporting its efficacy. That said, will the bureaucrats dig in their heels? Hard to say. There are three items I'm looking at in the upcoming earnings release: 1. Revenues. They don't break out thyroid and pancreas. In Q4 did they get $10-$11MM total revenues? Did they break the $42MM revenue marker for the year? How much of that growth was in the relatively safe thyroid? (might not break out) 2. Cash on hand. This is huge if they lose PancraGen. They paid down a bunch of debt and got rid of the LOC. I'm hoping for $5MM. 3. Debt remaining. The LOC is gone. They paid $2.5MM to get rid of $3.0MM in debt. I am guessing that there's $7MM-$8MM left. Debt is now interest only. But a strong Q4? Maybe they paid some down.

Esau815 Posted - 02/26/24

$IDXG Things just got interesting. 1. Future of $IDXG rests on the reimbursement of PancraGen. 2. Novitas initially rejected reimbursement because of efficacy concerns. 3. Now you have a respected world leading organization saying, "Yes it works". 4. Is this enough for Novitas to back down? Or are they like other governmental entities who refuse to back down? Answer? Difference between a company struggling to survive and a company whose stock will go up considerably if it gets a favorable ruling.

Zapp Posted - 02/20/24

$IDXG

Esau815 Posted - 02/15/24

$IDXG Should Novitas drop their reimbursement objections to PancraGen that would lift the cloud hanging over the share price. I have no idea whether or not that will occur.

Esau815 Posted - 02/12/24

$IDXG To Waters. The big issue is continued reimbursement for Pancragen by CMS. It could go either way though I've heard that $IDXG put up a compelling case and that Novitas simply made a mistake. That said, there's no certainty. With PancraGen $IDXG would have $40MM in revenues. They could get rid of what I believe to be about $7MM in debt. Just the extra year with PancraGen from the original 2023 pronouncement was a lifesaver.